



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: 37945-0024

Applicant(s): Richard Anthony Godwin SMITH *et al.*

RECEIVED

Serial No.: 09/936,205

Confirmation No.: 2596

MAR 04 2002

Filing Date: September 10, 2001

TECH CENTER 1600/2900

Title: ORGAN TRANSPLANT SOLUTIONS CONTAINING CONJUGATES OF SOLUBLE PEPTIDIC COMPOUNDS WITH MEMBRANE-BINDING

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56 and 37 CFR §1.97**

Commissioner for Patents
Washington, D.C. 20231

Sir:

Submitted herewith on Form PTO/SB/08A is a listing of documents known to applicants in order to comply with applicants' duty of disclosure pursuant to 37 C.F.R. §1.56 and §1.97. A copy of each of the listed documents are being submitted to comply with the provisions of 37 C.F.R. §1.97-1.99.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or is considered to be material to patentability as defined in 37 C.F.R. §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* prior art reference against the claims of the present application.

Applicants believe that the instant Information Disclosure Statement is being filed before the mailing of a first Office Action on the merits under 37 CFR §1.97(b)(3), therefore, no fee is required in connection with its filing.


U.S. Serial No. 09/936,205

English translations of the foreign-language documents may not be readily available; however, the absence of such translations does not relieve the PTO from its duty to consider the submitted documents (37 CFR §1.98 and MPEP §609).

Applicants respectfully request that the listed documents be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08A be returned in accordance with M.P.E.P. §609.

Respectfully submitted,

January 25, 2002
Date


John P. Isacson
Reg. No. 33,715

HELLER EHRMAN WHITE & MCAULIFFE
1666 K Street, N.W., Suite 300
Washington, D.C. 20006
Phone: (202) 912-2000
Fax: (202) 912-2020



THE COMMISSIONER IS HEREBY AUTHORIZED TO CHARGE ANY DEFICIENCY OR CREDIT ANY
OVERPAYMENT TO DEPOSIT ACCOUNT NO. 08-1641.

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

ATTY DOCKET NO.
37945-0024

SERIAL NO.
09/936,205

APPLICANT
Richard Anthony Godwin SMITH et al.

FILING DATE
September 10, 2001

GROUP
T be assigned

Date Submitted: **January 25, 2002**

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE (M/D/Y)	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	B01	5,843,778	12/1/98	ROSENGARD et al.	435	325	
	B02	5,847,082	12/8/98	ROTHER et al.	530	350	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE (M/D/Y)	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	B03	WO89/09220		WIPO			
	B04	WO 91/05047		WIPO			

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

	B05	Bach et al.	Immunol Rev. 141: 5-30 (1994)
	B06	Blackshear	J. Biol. Chem. 268: 1501-1504 (1993)
	B07	Brasile et al.	Transplant Proc. 19: 894-895 (1987)
	B08	Buysmann et al.	Transplantation 64: 1620-1623 (1997)
	B09	Dupe et al.	Thrombosis & Haemostasis 65(6): 695 (1991)
	B10	Fujino et al.	J. Heart Lung Transplant 16: 1073-1080 (1997)
	B11	Hauet et al.	Transplantation 64: 1082-1086 (1997)
	B12	Ho et al.	Clin. Immunol. Immunopatrol. 80: 540-545 (1996)
	B13	Hourcade et al.	J. Exp. Med. 168: 1255-1270 (1988)
	B14	Klickstein et al.	J. Exp. Med. 165: 1095-1112 (1987)
	B15	Koyamada et al.	Transplantation 65: 1210-1215 (1998)
	B16	Krych et al.	FASEB J. 3(A): 368 (1989)
	B17	Krych et al.	PNAS 88: 4353-4357 (1991)
	B18	McLaughlin et al.	TIBS 20: 272-276 (1994)
	B19	Mikata et al.	Transplant Immunol. 2: 107-110 (1998)
	B20	Morgan	The Biological Effects Of Complement Activation. In: Complement, Clinical Aspects And Relevant To Disease, Academic Press, London (1990)
	B21	Oberpenning et al.	Nature Biotech., 17, 149-155 (1999)
	B22	Piddlesden et al.	J. Immunol. 152: 5477-5484 (1994)


EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION DISCLOSURE
BY APPLICANT**

Date Submitted: January 25, 2002


 ATTY DOCKET NO.
37945-0024

 SERIAL NO.
09/936,205

MAR 04 2002

 APPLICANT
Richard Anthony Godwin SMITH et al.

TECH CENTER 1600/2900

 FILING DATE
September 10, 2001

 GROUP
To be assigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE (M/D/Y)	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE (M/D/Y)	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

B23	Pratt et al.	Am. J. Pathol. 199: 2055-2066 (1996)
B24	Pratt et al.	Eur. J. Immunol. 27: 2848-2853 (1997)
B25	Pruitt et al.	J. Surg. Res. 50: 350-355 (1991)
B26	Pruitt et al.	Transplantation 52: 868-873 (1991)
B27	Pruitt et al.	Transplantation 57: 363-370 (1994)
B28	Rossen et al.	Circ. Res. 57: 119-130 (1985)
B29	Sheerin et al.	Curr. Opin. Nephrol. Hypertens 7: 305-310 (1998)
B30	Weisman et al.	Science. 249: 146-151 (1990)
B31	Yeatman et al.	Transplantation 65: 1084-1093 (1998)
B32	Yeh et al.	J. Immunol. 146: 250 (1991)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.